Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 3Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 33Lymphoma, Follicular 19Lymphoma, Non-Hodgkin 16Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 5Recurrence 4Neoplasms 3Leukemia, Hairy Cell 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Tumor Lysis Syndrome 1Solid Tumors 1Solid Cancers 1Oncology Patients Receiving Chemotherapy 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Leukemia 1Disease 1Colorectal Neoplasms 1Chromosome 17 deletion 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 227Cytarabine 194fludarabine phosphate 138Methotrexate 132Filgrastim 127Busulfan 103Etoposide 99Peripheral Blood Stem Cell Transplantation 91Rituximab 81fludarabine 77Radiotherapy 77Vincristine 74Daunorubicin 68Antilymphocyte Serum 65Cyclosporine 63Dexamethasone 61Tacrolimus 56Mycophenolic Acid 53Melphalan 52Imatinib Mesylate 50Granulocyte Colony-Stimulating Factor 50Mercaptopurine 46Whole-Body Irradiation 45Idarubicin 43sargramostim 42Methylprednisolone 42Doxorubicin 41Flow Cytometry 40Prednisone 39Clofarabine 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia × obinutuzumab × Clear all
NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

BeiGene

Phase 1 Completed
119 enrolled 34 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡